Meeting
2024 ASCO Genitourinary Cancers Symposium
Trends in local therapy utilization and survival of patients with de-novo metastatic prostate cancer treated by hormone therapy with or without systemic therapy intensification with chemotherapy.
Authors
Siqi Hu
Houston Methodist Hospital, Houston, TX
Siqi Hu , Zachary Melchiode , Jiaqiong Xu , Carlos Riveros , Emily Huang , Dharam Kaushik , Andrew M. Farach , Brian Miles , Guru P. Sonpavde , Eleni Efstathiou , Christopher J.D. Wallis , Raj Satkunasivam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 90)
DOI
10.1200/JCO.2024.42.4_suppl.90
Abstract #
90
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Role of metastases-directed therapy (MDT) in the management of solitary metastatic prostate cancer.
First Author: Mohamed E. Ahmed
First Author: Nellie Nafissi
Poster
2024 ASCO Annual Meeting
Health-related quality of life (QoL) in randomized phase III trials in oncology: Association between results of QoL, results of primary endpoint and drug approval.
First Author: Chiara Paratore
Poster
2024 ASCO Genitourinary Cancers Symposium
Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): A phase II trial for veterans with de novo oligometastatic prostate cancer.
First Author: Nicholas George Nickols